Clinical Updates from Phase 2a Studies with Optimised Consortia Therapeutic MH002 in Ulcerative Colitis & Pouchitis
Time: 8:30 am
day: Conference Day One
Details:
- MH002, a 6-strain consortia therapeutic designed, optimised and manufactured through MRM Health’s CORAL® technology, is the most advanced live biotherapeutic in clinical development for Ulcerative Colitis and Pouchitis
- Having completed full analysis, sharing additional insights of MH002’s activity
- Sharing microbiome and engraftment data, for the mechanism of action of MH002
